Group 1 - The core point of the news is that Yinos Biotech has seen a stock price increase of 5.12%, reaching 59.50 CNY per share, with a total market capitalization of 8.388 billion CNY as of the report date [1] - Yinos Biotech, established on May 12, 2010, is located in the China (Shanghai) Pilot Free Trade Zone and specializes in providing non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services [1] - The company is set to be listed on September 3, 2024, indicating a future growth opportunity for investors [1] Group 2 - According to fund data, Yinos Biotech is a significant holding in the Xinda Aoya Fund, specifically in the Xinao Enjoy Life Mixed A Fund (017977), which held 903,500 shares, accounting for 5.65% of the fund's net value [2] - The Xinao Enjoy Life Mixed A Fund has achieved a year-to-date return of 11.67% and a one-year return of 43.56%, ranking 1887 out of 8891 and 1829 out of 8137 respectively among its peers [2] - The fund manager, Yang Ke, has been in charge for nearly six years, with the fund's total assets amounting to 706 million CNY and a best return of 39.06% during his tenure [2]
益诺思股价涨5.12%，信达澳亚基金旗下1只基金重仓，持有90.35万股浮盈赚取262.01万元